Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

PRTK

Paratek Pharmaceuticals (PRTK)

Paratek Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PRTK
FechaHoraFuenteTítuloSímboloCompañía
05/10/202307:00GlobeNewswire Inc.Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023NASDAQ:PRTKParatek Pharmaceuticals Inc
02/10/202306:33Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:PRTKParatek Pharmaceuticals Inc
25/09/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRTKParatek Pharmaceuticals Inc
21/09/202312:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRTKParatek Pharmaceuticals Inc
21/09/202309:59Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRTKParatek Pharmaceuticals Inc
21/09/202309:42Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRTKParatek Pharmaceuticals Inc
21/09/202309:39Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PRTKParatek Pharmaceuticals Inc
21/09/202308:10Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:PRTKParatek Pharmaceuticals Inc
21/09/202308:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRTKParatek Pharmaceuticals Inc
21/09/202307:58GlobeNewswire Inc.Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.NASDAQ:PRTKParatek Pharmaceuticals Inc
12/09/202316:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PRTKParatek Pharmaceuticals Inc
09/08/202313:37Business WireInvestor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek Stockholders to Contact Abbott Cooper Regarding Their Legal RightsNASDAQ:PRTKParatek Pharmaceuticals Inc
03/08/202307:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRTKParatek Pharmaceuticals Inc
03/08/202307:00GlobeNewswire Inc.Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 MillionNASDAQ:PRTKParatek Pharmaceuticals Inc
02/08/202316:03Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:PRTKParatek Pharmaceuticals Inc
28/07/202311:55Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:PRTKParatek Pharmaceuticals Inc
11/07/202315:15PR Newswire (US)NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point CapitalNASDAQ:PRTKParatek Pharmaceuticals Inc
10/07/202307:00GlobeNewswire Inc.Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary AnthraxNASDAQ:PRTKParatek Pharmaceuticals Inc
30/06/202309:38Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:PRTKParatek Pharmaceuticals Inc
30/06/202308:16Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:PRTKParatek Pharmaceuticals Inc
30/06/202308:16Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:PRTKParatek Pharmaceuticals Inc
27/06/202311:01GlobeNewswire Inc.Paratek Pharmaceuticals Acknowledges Receipt of NexPoint LetterNASDAQ:PRTKParatek Pharmaceuticals Inc
27/06/202307:21Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PRTKParatek Pharmaceuticals Inc
27/06/202307:00GlobeNewswire Inc.European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:PRTKParatek Pharmaceuticals Inc
27/06/202307:00PR Newswire (US)NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point CapitalNASDAQ:PRTKParatek Pharmaceuticals Inc
07/06/202305:12Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PRTKParatek Pharmaceuticals Inc
07/06/202305:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PRTKParatek Pharmaceuticals Inc
06/06/202317:38Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:PRTKParatek Pharmaceuticals Inc
06/06/202308:59Dow Jones NewsParatek Pharmaceuticals to Be Acquired in Deal Worth Up to $462 MillionNASDAQ:PRTKParatek Pharmaceuticals Inc
09/05/202315:57Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:PRTKParatek Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PRTK